SlideShare uma empresa Scribd logo
1 de 16
Visualize the pharma twittersphere


Friday, January 29, 2010
Over	
  past	
  18	
  month	
  big	
  pharma	
  set	
  up	
  a	
  
                                       presence	
  on	
  twiJer


                                                       Start	
  of	
  twiJer	
  ac1vi1es

                     2008                                                            2009                                         2010



         @Boehringer @AstraZenecaUS @JNJComm @Amgen           @Pfizernews
         @Novar1s                   @Roche_com @genentechnews @AstraZeneca
                                               @GSKUS




                               Whydot twitter analysis




                           Source:	
  www.twiJer.com,	
  July	
  13th	
  and	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis     2

Friday, January 29, 2010
Pfizer	
  leads	
  in	
  terms	
  of	
  followers	
  despite	
  late	
  start

  #	
  of	
  Followers




                                                                                                                                      	
  2	
  699




                                                                                                                                      1	
  313




                                  Avg	
  Dec	
  09
                                  Avg	
  Jul	
  09

                           Source:	
  www.twiJer.com,	
  July	
  13th	
  and	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis   3

Friday, January 29, 2010
Great	
  divide	
  on	
  following	
  policy	
  amongst	
  pharma

            #	
  of	
  Following




                                                                                                                                      	
  600

                                                                                                                                      392




                                   Avg	
  Dec	
  09
                                   Avg	
  Jul	
  09
                           Source:	
  www.twiJer.com,	
  July	
  13th	
  and	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis   4

Friday, January 29, 2010
Difference	
  in	
  updates	
  =	
  different	
  degrees	
  of	
  engagement?
        #	
  of	
  Updates




                                                                                                                                      	
  255


                                                                                                                                      119




                                  Avg	
  Dec	
  09
                                  Avg	
  Jul	
  09

                           Source:	
  www.twiJer.com,	
  July	
  13th	
  and	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis   5

Friday, January 29, 2010
Boehringer	
  &	
  JNJ	
  lead	
  in	
  terms	
  of	
  engagement
     #	
  of	
  Following




                 Average	
  following:	
  392




                                         Average	
  Updates:	
  119                                                                                            #	
  of	
  Updates
                                                                                                                 Bubble	
  size	
  =	
  #	
  of	
  followers
                            Source:	
  www.twiJer.com,	
  July	
  13th	
  and	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis

Friday, January 29, 2010
Boehringer	
  &	
  JNJ	
  lead	
  in	
  terms	
  of	
  engagement
     #	
  of	
  Following




                                                                   The twitter engagement
                                                                   quardrant: above
                                                                   average followers,
                                                                   following and updates!
                 Average	
  following:	
  392




                                         Average	
  Updates:	
  119                                                                                            #	
  of	
  Updates
                                                                                                                 Bubble	
  size	
  =	
  #	
  of	
  followers
                            Source:	
  www.twiJer.com,	
  July	
  13th	
  and	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis

Friday, January 29, 2010
...	
  Roche	
  &	
  AstraZeneca	
  moving	
  into	
  the	
  “engagement“	
  quadrant

      #	
  of	
  Following




                              @Pfizer_news



                        Avrg	
  following:	
  600

                       @genentechnews




                                                 Avrg	
  Updates:	
  255                                                                                              #	
  of	
  Updates
                                                                                                                Avrg	
  Bubble	
  size	
  =	
  #	
  of	
  followers
                           Source:	
  www.twiJer.com,	
  July	
  13th	
  and	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis

Friday, January 29, 2010
19%	
  of	
  pharma	
  followers,	
  or	
  3,034	
  twiJer	
  accounts	
  have	
  
           more	
  than	
  500	
  followers.

                                                                                              % >500 followers


                                                                                                     15%
                                                                                                     14%
                                                                                                     26%
                                                                                                     20%
                                                                                                     20%
                                                                                                  Avrg 19%
          Number of followers that
          are followed by




              Source:	
  www.twiJer.com,	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis

                                                                                                 8

Friday, January 29, 2010
32%	
  of	
  accounts	
  follow	
  more	
  than	
  1	
  pharma	
  account


                                                                    !"#$%&'($)*$&+"%%",-).&/0122&+"%%",-).3&
                                                                                               &4&5256&$77"89#.&&




                                                                   :77"89#.&+"%%",;9<&*")-&#($9&=&$77"89#&
                                                                                                   45>?&"@-)%$'&



                                                                                                               =
                                                                             2,079	
  unique	
  twiJer	
  accounts
      Note:	
  Analysis	
  based	
  on	
  19%	
  accounts	
  with	
  >500	
  followers	
  that	
  follow	
  at	
  least	
  one	
  of	
  the	
  5	
  pharma	
  accounts	
  listed	
  above
      Source:	
  www.twiJer.com,	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis
                                                                                                                                                                         9

Friday, January 29, 2010
Boehringer	
  &	
  JNJ	
  :	
  number	
  of	
  followers	
  with	
  >	
  2000	
  followers	
  




                   2000-­‐	
  5000	
  followers
                   >	
  5000	
  followers

              Source:	
  www.twiJer.com,	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis
                                                                                                     10

Friday, January 29, 2010
Segmented	
  2,079	
  unique	
  pharma	
  followers	
  into	
  6	
  segments

          Service	
  providers:	
  	
  	
  	
  	
  Consul1ng	
  services,	
  agencies,	
  CROs,	
  pharma	
  vendors,	
  etc.

          Journalist/bloggers:	
  Trade,	
  industry	
  and	
  health	
  publica1ons,	
  
                            	
  	
  	
  	
  	
  journalists,	
  financial	
  analysts,	
  healthcare	
  bloggers	
  etc.

          Advocacy:	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  Pa1ent	
  advocacy,	
  cause/awareness	
  advocacy	
  etc.

          HCP/Stakeholders:	
  	
  	
  	
  Physicians,	
  nurses,	
  regulators,	
  insurance	
  etc.

          Science/academia:	
  	
  	
  	
  Scien1sts,	
  scien1fic	
  publica1ons,	
  faculty	
  etc.

          Other:	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  Other	
  pharma	
  companies,	
  pharma	
  employees,	
  
                                                                                                         	
  	
  	
  	
  	
  health	
  websites,	
  travel	
  vendors,	
  real	
  estate	
  agents,	
  other	
  	
  	
  
                                                                                                         	
  	
  	
  	
  	
  vendors	
  individuals,	
  non-­‐iden1fiable	
  accounts

      Source:	
  www.twiJer.com,	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis
                                                                                                                                                                                         11

Friday, January 29, 2010
Service	
  providers,	
  journalists,	
  bloggers	
  and	
  
        advocates	
  make	
  up	
  57%	
  of	
  pharma	
  following

                                   !"#$%&'()'*+,-%&'.//("0*1'23455')(66(+%&17')(66(+,08'*(9'4'9:.&#.'.//("0*1'
                                                          '304$)5&'6$/078/9$:--./012;$



         ,--./012$                             !"#$                                                   !%#$                                   ""#$             "&#$           '#$       (#$




                      &#$                             )&#$                             *&#$                             %&#$                             +&#$                               "&&#$

                         <1=9>$         ?9>@7-9$A>.@7B9>$            C./>0:D721EFD.GG9>2$             ,B@.-:-H$           IJKE?1:L9=.DB9>2$              ?-790M212E,-:B9N7:$




      Note:	
  Analysis	
  based	
  on	
  19%	
  accounts	
  with	
  >500	
  followers	
  that	
  follow	
  at	
  least	
  one	
  of	
  the	
  5	
  pharma	
  accounts	
  listed	
  above
      Source:	
  www.twiJer.com,	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis
                                                                                                                                                                        12

Friday, January 29, 2010
Service	
  providers	
  and	
  Journalist/bloggers	
  also	
  follow	
  most	
  of	
  the	
  pharma	
  
         accounts	
  with	
  an	
  overlap	
  of	
  36%	
  and	
  41%	
  respec1vely




                   Service	
  providers
                   Journalist/bloggers

             Source:	
  www.twiJer.com,	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis            13

Friday, January 29, 2010
Boehringer	
  counts	
  most	
  journalists	
  and	
  bloggers	
  
     amongst	
  its	
  followers,	
  while	
  JNJ	
  porholio	
  is	
  more	
  diverse
                         !"#$%&'()'*+,-%&')(..(+%&/'01233')(..(+%&/4'5%&'567&#7'788("9*/'$:'/*7;%6(.<%&'/%=#%9*'                                                                              Number followers
                                                           F6G$&H)&($:CC.I3J<K$                                                                                                                   (>500)

          D9/1:4/E$                          &'#$                                             &+#$                               ''#$                  ')#$               %#$     *#$          Unique 2,079*

       B.C0/@7.8$                         !%#$                                         &*#$                              '&#$                   ''#$                *#$         "#$                   506

       =>?/1@3/A<$                        !%#$                                            ('#$                                    '!#$                  ,#$           %#$        +#$                  580

            6.9:1;<$                      !%#$                                            ()#$                                    '(#$                  %#$         (#$         ,#$                   535

          5657.88$                         !"#$                                               (!#$                                       ''#$                 "#$          +#$    (#$                 544

        -./01234/1$                       !"#$                                         &(#$                               '*#$                   ')#$                "#$         +#$                  869

                        )#$                         !)#$                        ()#$                         +)#$                               ")#$                                  '))#$
                                                                                                                                                                                               Total 3,074
                    LJ0/1$       M/192C/$N1.92O/1$          5.I13:P2<JQRP.44/1<$          DO9.C:CS$         T7=QMJ:U/0.PO/1<$               MC2/3;<J<QDC:O/82:$



      *	
  Excluding	
  overlap	
  of	
  32%	
  
      Note:	
  Analysis	
  based	
  on	
  19%	
  accounts	
  with	
  >500	
  followers	
  that	
  follow	
  at	
  least	
  one	
  of	
  the	
  5	
  pharma	
  accounts	
  listed	
  above


     Source:	
  www.twiJer.com,	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis
                                                                                                                                                                                        14

Friday, January 29, 2010
Novar1s	
  high	
  overlap	
  with	
  others,	
  Boehringer	
  followed	
  by	
  many	
  
         journalists,	
  bloggers	
  and	
  advocates	
  alone.




                   Advocates
                   Journalist/bloggers

              Source:	
  www.twiJer.com,	
  Dec	
  31st	
  2009;	
  whdotpharma	
  analysis
                                                                                              15

Friday, January 29, 2010

Mais conteúdo relacionado

Destaque

Happy Mothers Day, MoMo
Happy Mothers Day, MoMoHappy Mothers Day, MoMo
Happy Mothers Day, MoMoaboice
 
George_Hinkle_techwritingresume
George_Hinkle_techwritingresumeGeorge_Hinkle_techwritingresume
George_Hinkle_techwritingresumeGeorge Hinkle
 
Gémeos 4ºA Alexandre e Diogo-Vanda Furtado
Gémeos 4ºA   Alexandre e Diogo-Vanda FurtadoGémeos 4ºA   Alexandre e Diogo-Vanda Furtado
Gémeos 4ºA Alexandre e Diogo-Vanda Furtadopoletef
 
Slide shareimagefb proffitt
Slide shareimagefb proffittSlide shareimagefb proffitt
Slide shareimagefb proffittSelf-employed
 
Research on career
Research on career Research on career
Research on career Thomas Smith
 
Zerbitzurako Sakramentuak
Zerbitzurako SakramentuakZerbitzurako Sakramentuak
Zerbitzurako SakramentuakColegio
 
Dampyr vec 020 - dvorac u-karpatima
Dampyr   vec 020 - dvorac u-karpatimaDampyr   vec 020 - dvorac u-karpatima
Dampyr vec 020 - dvorac u-karpatimaDino dino
 
Christensen-Career Planning-Assignment-Personal Branding
Christensen-Career Planning-Assignment-Personal BrandingChristensen-Career Planning-Assignment-Personal Branding
Christensen-Career Planning-Assignment-Personal BrandingCathy Christensen
 

Destaque (14)

Bioter
BioterBioter
Bioter
 
Happy Mothers Day, MoMo
Happy Mothers Day, MoMoHappy Mothers Day, MoMo
Happy Mothers Day, MoMo
 
George_Hinkle_techwritingresume
George_Hinkle_techwritingresumeGeorge_Hinkle_techwritingresume
George_Hinkle_techwritingresume
 
resume4
resume4resume4
resume4
 
Gémeos 4ºA Alexandre e Diogo-Vanda Furtado
Gémeos 4ºA   Alexandre e Diogo-Vanda FurtadoGémeos 4ºA   Alexandre e Diogo-Vanda Furtado
Gémeos 4ºA Alexandre e Diogo-Vanda Furtado
 
Slide shareimagefb proffitt
Slide shareimagefb proffittSlide shareimagefb proffitt
Slide shareimagefb proffitt
 
Research on career
Research on career Research on career
Research on career
 
Zerbitzurako Sakramentuak
Zerbitzurako SakramentuakZerbitzurako Sakramentuak
Zerbitzurako Sakramentuak
 
TURNER
TURNERTURNER
TURNER
 
Dampyr vec 020 - dvorac u-karpatima
Dampyr   vec 020 - dvorac u-karpatimaDampyr   vec 020 - dvorac u-karpatima
Dampyr vec 020 - dvorac u-karpatima
 
Christensen-Career Planning-Assignment-Personal Branding
Christensen-Career Planning-Assignment-Personal BrandingChristensen-Career Planning-Assignment-Personal Branding
Christensen-Career Planning-Assignment-Personal Branding
 
KMPS Project Documentation
KMPS Project DocumentationKMPS Project Documentation
KMPS Project Documentation
 
Koch Modular Process Systems
Koch Modular Process SystemsKoch Modular Process Systems
Koch Modular Process Systems
 
Informational Interview
Informational InterviewInformational Interview
Informational Interview
 

Mais de Silja Chouquet

Revealing ASCO's social DNA
Revealing ASCO's social DNARevealing ASCO's social DNA
Revealing ASCO's social DNASilja Chouquet
 
Biosimilars discussion on Twitter
Biosimilars discussion on TwitterBiosimilars discussion on Twitter
Biosimilars discussion on TwitterSilja Chouquet
 
Infographic Healthcare Archetypes of conversation
Infographic Healthcare Archetypes of conversation Infographic Healthcare Archetypes of conversation
Infographic Healthcare Archetypes of conversation Silja Chouquet
 
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitter
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitterA healthcare case study of ASCO, Novartis and Boehringer conversation on twitter
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitterSilja Chouquet
 
Three things to know about pharma and twitter
Three things to know about pharma and twitterThree things to know about pharma and twitter
Three things to know about pharma and twitterSilja Chouquet
 
Impact of social media on patient adherence
Impact of social media on patient adherenceImpact of social media on patient adherence
Impact of social media on patient adherenceSilja Chouquet
 
Digipharm workshop2011
Digipharm workshop2011Digipharm workshop2011
Digipharm workshop2011Silja Chouquet
 
20110126smiwhydotpresentation
20110126smiwhydotpresentation20110126smiwhydotpresentation
20110126smiwhydotpresentationSilja Chouquet
 
20100906 hcsmeu digipharmpres
20100906 hcsmeu digipharmpres20100906 hcsmeu digipharmpres
20100906 hcsmeu digipharmpresSilja Chouquet
 
HCSMEU Mission statement
HCSMEU Mission statementHCSMEU Mission statement
HCSMEU Mission statementSilja Chouquet
 
HCSMEU Mission statement
HCSMEU Mission statementHCSMEU Mission statement
HCSMEU Mission statementSilja Chouquet
 
3 3 Globalization Kalyanpur
3 3 Globalization Kalyanpur3 3 Globalization Kalyanpur
3 3 Globalization KalyanpurSilja Chouquet
 
3 2 Globalization Schweitzer
3 2 Globalization Schweitzer3 2 Globalization Schweitzer
3 2 Globalization SchweitzerSilja Chouquet
 
3 1 Globalization Hoogland
3 1 Globalization Hoogland3 1 Globalization Hoogland
3 1 Globalization HooglandSilja Chouquet
 
2 3 Consumer Gritschneder
2 3 Consumer Gritschneder2 3 Consumer Gritschneder
2 3 Consumer GritschnederSilja Chouquet
 

Mais de Silja Chouquet (20)

Revealing ASCO's social DNA
Revealing ASCO's social DNARevealing ASCO's social DNA
Revealing ASCO's social DNA
 
Biosimilars discussion on Twitter
Biosimilars discussion on TwitterBiosimilars discussion on Twitter
Biosimilars discussion on Twitter
 
Infographic Healthcare Archetypes of conversation
Infographic Healthcare Archetypes of conversation Infographic Healthcare Archetypes of conversation
Infographic Healthcare Archetypes of conversation
 
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitter
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitterA healthcare case study of ASCO, Novartis and Boehringer conversation on twitter
A healthcare case study of ASCO, Novartis and Boehringer conversation on twitter
 
Three things to know about pharma and twitter
Three things to know about pharma and twitterThree things to know about pharma and twitter
Three things to know about pharma and twitter
 
Ideagoras
IdeagorasIdeagoras
Ideagoras
 
Impact of social media on patient adherence
Impact of social media on patient adherenceImpact of social media on patient adherence
Impact of social media on patient adherence
 
Pecha kucha
Pecha kuchaPecha kucha
Pecha kucha
 
Digipharm workshop2011
Digipharm workshop2011Digipharm workshop2011
Digipharm workshop2011
 
20110126smiwhydotpresentation
20110126smiwhydotpresentation20110126smiwhydotpresentation
20110126smiwhydotpresentation
 
20100906 hcsmeu digipharmpres
20100906 hcsmeu digipharmpres20100906 hcsmeu digipharmpres
20100906 hcsmeu digipharmpres
 
Kalkscheune
KalkscheuneKalkscheune
Kalkscheune
 
HCSMEU Mission statement
HCSMEU Mission statementHCSMEU Mission statement
HCSMEU Mission statement
 
Powervote Results
Powervote ResultsPowervote Results
Powervote Results
 
HCSMEU Mission statement
HCSMEU Mission statementHCSMEU Mission statement
HCSMEU Mission statement
 
3 3 Globalization Kalyanpur
3 3 Globalization Kalyanpur3 3 Globalization Kalyanpur
3 3 Globalization Kalyanpur
 
3 2 Globalization Schweitzer
3 2 Globalization Schweitzer3 2 Globalization Schweitzer
3 2 Globalization Schweitzer
 
3 1 Globalization Hoogland
3 1 Globalization Hoogland3 1 Globalization Hoogland
3 1 Globalization Hoogland
 
2 3 Consumer Gritschneder
2 3 Consumer Gritschneder2 3 Consumer Gritschneder
2 3 Consumer Gritschneder
 
Gto Consumer Apelles
Gto Consumer ApellesGto Consumer Apelles
Gto Consumer Apelles
 

Último

React Native vs Ionic - The Best Mobile App Framework
React Native vs Ionic - The Best Mobile App FrameworkReact Native vs Ionic - The Best Mobile App Framework
React Native vs Ionic - The Best Mobile App FrameworkPixlogix Infotech
 
JET Technology Labs White Paper for Virtualized Security and Encryption Techn...
JET Technology Labs White Paper for Virtualized Security and Encryption Techn...JET Technology Labs White Paper for Virtualized Security and Encryption Techn...
JET Technology Labs White Paper for Virtualized Security and Encryption Techn...amber724300
 
React JS; all concepts. Contains React Features, JSX, functional & Class comp...
React JS; all concepts. Contains React Features, JSX, functional & Class comp...React JS; all concepts. Contains React Features, JSX, functional & Class comp...
React JS; all concepts. Contains React Features, JSX, functional & Class comp...Karmanjay Verma
 
Generative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdfGenerative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdfIngrid Airi González
 
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyes
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyesHow to Effectively Monitor SD-WAN and SASE Environments with ThousandEyes
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyesThousandEyes
 
UiPath Community: Communication Mining from Zero to Hero
UiPath Community: Communication Mining from Zero to HeroUiPath Community: Communication Mining from Zero to Hero
UiPath Community: Communication Mining from Zero to HeroUiPathCommunity
 
Microsoft 365 Copilot: How to boost your productivity with AI – Part two: Dat...
Microsoft 365 Copilot: How to boost your productivity with AI – Part two: Dat...Microsoft 365 Copilot: How to boost your productivity with AI – Part two: Dat...
Microsoft 365 Copilot: How to boost your productivity with AI – Part two: Dat...Nikki Chapple
 
Abdul Kader Baba- Managing Cybersecurity Risks and Compliance Requirements i...
Abdul Kader Baba- Managing Cybersecurity Risks  and Compliance Requirements i...Abdul Kader Baba- Managing Cybersecurity Risks  and Compliance Requirements i...
Abdul Kader Baba- Managing Cybersecurity Risks and Compliance Requirements i...itnewsafrica
 
Digital Tools & AI in Career Development
Digital Tools & AI in Career DevelopmentDigital Tools & AI in Career Development
Digital Tools & AI in Career DevelopmentMahmoud Rabie
 
Manual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance AuditManual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance AuditSkynet Technologies
 
Long journey of Ruby standard library at RubyConf AU 2024
Long journey of Ruby standard library at RubyConf AU 2024Long journey of Ruby standard library at RubyConf AU 2024
Long journey of Ruby standard library at RubyConf AU 2024Hiroshi SHIBATA
 
Accelerating Enterprise Software Engineering with Platformless
Accelerating Enterprise Software Engineering with PlatformlessAccelerating Enterprise Software Engineering with Platformless
Accelerating Enterprise Software Engineering with PlatformlessWSO2
 
Design pattern talk by Kaya Weers - 2024 (v2)
Design pattern talk by Kaya Weers - 2024 (v2)Design pattern talk by Kaya Weers - 2024 (v2)
Design pattern talk by Kaya Weers - 2024 (v2)Kaya Weers
 
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...panagenda
 
Modern Roaming for Notes and Nomad – Cheaper Faster Better Stronger
Modern Roaming for Notes and Nomad – Cheaper Faster Better StrongerModern Roaming for Notes and Nomad – Cheaper Faster Better Stronger
Modern Roaming for Notes and Nomad – Cheaper Faster Better Strongerpanagenda
 
The Future Roadmap for the Composable Data Stack - Wes McKinney - Data Counci...
The Future Roadmap for the Composable Data Stack - Wes McKinney - Data Counci...The Future Roadmap for the Composable Data Stack - Wes McKinney - Data Counci...
The Future Roadmap for the Composable Data Stack - Wes McKinney - Data Counci...Wes McKinney
 
Bridging Between CAD & GIS: 6 Ways to Automate Your Data Integration
Bridging Between CAD & GIS:  6 Ways to Automate Your Data IntegrationBridging Between CAD & GIS:  6 Ways to Automate Your Data Integration
Bridging Between CAD & GIS: 6 Ways to Automate Your Data Integrationmarketing932765
 
Generative AI - Gitex v1Generative AI - Gitex v1.pptx
Generative AI - Gitex v1Generative AI - Gitex v1.pptxGenerative AI - Gitex v1Generative AI - Gitex v1.pptx
Generative AI - Gitex v1Generative AI - Gitex v1.pptxfnnc6jmgwh
 
Top 10 Hubspot Development Companies in 2024
Top 10 Hubspot Development Companies in 2024Top 10 Hubspot Development Companies in 2024
Top 10 Hubspot Development Companies in 2024TopCSSGallery
 
Tampa BSides - The No BS SOC (slides from April 6, 2024 talk)
Tampa BSides - The No BS SOC (slides from April 6, 2024 talk)Tampa BSides - The No BS SOC (slides from April 6, 2024 talk)
Tampa BSides - The No BS SOC (slides from April 6, 2024 talk)Mark Simos
 

Último (20)

React Native vs Ionic - The Best Mobile App Framework
React Native vs Ionic - The Best Mobile App FrameworkReact Native vs Ionic - The Best Mobile App Framework
React Native vs Ionic - The Best Mobile App Framework
 
JET Technology Labs White Paper for Virtualized Security and Encryption Techn...
JET Technology Labs White Paper for Virtualized Security and Encryption Techn...JET Technology Labs White Paper for Virtualized Security and Encryption Techn...
JET Technology Labs White Paper for Virtualized Security and Encryption Techn...
 
React JS; all concepts. Contains React Features, JSX, functional & Class comp...
React JS; all concepts. Contains React Features, JSX, functional & Class comp...React JS; all concepts. Contains React Features, JSX, functional & Class comp...
React JS; all concepts. Contains React Features, JSX, functional & Class comp...
 
Generative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdfGenerative Artificial Intelligence: How generative AI works.pdf
Generative Artificial Intelligence: How generative AI works.pdf
 
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyes
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyesHow to Effectively Monitor SD-WAN and SASE Environments with ThousandEyes
How to Effectively Monitor SD-WAN and SASE Environments with ThousandEyes
 
UiPath Community: Communication Mining from Zero to Hero
UiPath Community: Communication Mining from Zero to HeroUiPath Community: Communication Mining from Zero to Hero
UiPath Community: Communication Mining from Zero to Hero
 
Microsoft 365 Copilot: How to boost your productivity with AI – Part two: Dat...
Microsoft 365 Copilot: How to boost your productivity with AI – Part two: Dat...Microsoft 365 Copilot: How to boost your productivity with AI – Part two: Dat...
Microsoft 365 Copilot: How to boost your productivity with AI – Part two: Dat...
 
Abdul Kader Baba- Managing Cybersecurity Risks and Compliance Requirements i...
Abdul Kader Baba- Managing Cybersecurity Risks  and Compliance Requirements i...Abdul Kader Baba- Managing Cybersecurity Risks  and Compliance Requirements i...
Abdul Kader Baba- Managing Cybersecurity Risks and Compliance Requirements i...
 
Digital Tools & AI in Career Development
Digital Tools & AI in Career DevelopmentDigital Tools & AI in Career Development
Digital Tools & AI in Career Development
 
Manual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance AuditManual 508 Accessibility Compliance Audit
Manual 508 Accessibility Compliance Audit
 
Long journey of Ruby standard library at RubyConf AU 2024
Long journey of Ruby standard library at RubyConf AU 2024Long journey of Ruby standard library at RubyConf AU 2024
Long journey of Ruby standard library at RubyConf AU 2024
 
Accelerating Enterprise Software Engineering with Platformless
Accelerating Enterprise Software Engineering with PlatformlessAccelerating Enterprise Software Engineering with Platformless
Accelerating Enterprise Software Engineering with Platformless
 
Design pattern talk by Kaya Weers - 2024 (v2)
Design pattern talk by Kaya Weers - 2024 (v2)Design pattern talk by Kaya Weers - 2024 (v2)
Design pattern talk by Kaya Weers - 2024 (v2)
 
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
Why device, WIFI, and ISP insights are crucial to supporting remote Microsoft...
 
Modern Roaming for Notes and Nomad – Cheaper Faster Better Stronger
Modern Roaming for Notes and Nomad – Cheaper Faster Better StrongerModern Roaming for Notes and Nomad – Cheaper Faster Better Stronger
Modern Roaming for Notes and Nomad – Cheaper Faster Better Stronger
 
The Future Roadmap for the Composable Data Stack - Wes McKinney - Data Counci...
The Future Roadmap for the Composable Data Stack - Wes McKinney - Data Counci...The Future Roadmap for the Composable Data Stack - Wes McKinney - Data Counci...
The Future Roadmap for the Composable Data Stack - Wes McKinney - Data Counci...
 
Bridging Between CAD & GIS: 6 Ways to Automate Your Data Integration
Bridging Between CAD & GIS:  6 Ways to Automate Your Data IntegrationBridging Between CAD & GIS:  6 Ways to Automate Your Data Integration
Bridging Between CAD & GIS: 6 Ways to Automate Your Data Integration
 
Generative AI - Gitex v1Generative AI - Gitex v1.pptx
Generative AI - Gitex v1Generative AI - Gitex v1.pptxGenerative AI - Gitex v1Generative AI - Gitex v1.pptx
Generative AI - Gitex v1Generative AI - Gitex v1.pptx
 
Top 10 Hubspot Development Companies in 2024
Top 10 Hubspot Development Companies in 2024Top 10 Hubspot Development Companies in 2024
Top 10 Hubspot Development Companies in 2024
 
Tampa BSides - The No BS SOC (slides from April 6, 2024 talk)
Tampa BSides - The No BS SOC (slides from April 6, 2024 talk)Tampa BSides - The No BS SOC (slides from April 6, 2024 talk)
Tampa BSides - The No BS SOC (slides from April 6, 2024 talk)
 

20100128 Pharma Twittersphere Part Ii

  • 1. Visualize the pharma twittersphere Friday, January 29, 2010
  • 2. Over  past  18  month  big  pharma  set  up  a   presence  on  twiJer Start  of  twiJer  ac1vi1es 2008 2009 2010 @Boehringer @AstraZenecaUS @JNJComm @Amgen @Pfizernews @Novar1s @Roche_com @genentechnews @AstraZeneca @GSKUS Whydot twitter analysis Source:  www.twiJer.com,  July  13th  and  Dec  31st  2009;  whdotpharma  analysis 2 Friday, January 29, 2010
  • 3. Pfizer  leads  in  terms  of  followers  despite  late  start #  of  Followers  2  699 1  313 Avg  Dec  09 Avg  Jul  09 Source:  www.twiJer.com,  July  13th  and  Dec  31st  2009;  whdotpharma  analysis 3 Friday, January 29, 2010
  • 4. Great  divide  on  following  policy  amongst  pharma #  of  Following  600 392 Avg  Dec  09 Avg  Jul  09 Source:  www.twiJer.com,  July  13th  and  Dec  31st  2009;  whdotpharma  analysis 4 Friday, January 29, 2010
  • 5. Difference  in  updates  =  different  degrees  of  engagement? #  of  Updates  255 119 Avg  Dec  09 Avg  Jul  09 Source:  www.twiJer.com,  July  13th  and  Dec  31st  2009;  whdotpharma  analysis 5 Friday, January 29, 2010
  • 6. Boehringer  &  JNJ  lead  in  terms  of  engagement #  of  Following Average  following:  392 Average  Updates:  119 #  of  Updates Bubble  size  =  #  of  followers Source:  www.twiJer.com,  July  13th  and  Dec  31st  2009;  whdotpharma  analysis Friday, January 29, 2010
  • 7. Boehringer  &  JNJ  lead  in  terms  of  engagement #  of  Following The twitter engagement quardrant: above average followers, following and updates! Average  following:  392 Average  Updates:  119 #  of  Updates Bubble  size  =  #  of  followers Source:  www.twiJer.com,  July  13th  and  Dec  31st  2009;  whdotpharma  analysis Friday, January 29, 2010
  • 8. ...  Roche  &  AstraZeneca  moving  into  the  “engagement“  quadrant #  of  Following @Pfizer_news Avrg  following:  600 @genentechnews Avrg  Updates:  255 #  of  Updates Avrg  Bubble  size  =  #  of  followers Source:  www.twiJer.com,  July  13th  and  Dec  31st  2009;  whdotpharma  analysis Friday, January 29, 2010
  • 9. 19%  of  pharma  followers,  or  3,034  twiJer  accounts  have   more  than  500  followers. % >500 followers 15% 14% 26% 20% 20% Avrg 19% Number of followers that are followed by Source:  www.twiJer.com,  Dec  31st  2009;  whdotpharma  analysis 8 Friday, January 29, 2010
  • 10. 32%  of  accounts  follow  more  than  1  pharma  account !"#$%&'($)*$&+"%%",-).&/0122&+"%%",-).3& &4&5256&$77"89#.&& :77"89#.&+"%%",;9<&*")-&#($9&=&$77"89#& 45>?&"@-)%$'& = 2,079  unique  twiJer  accounts Note:  Analysis  based  on  19%  accounts  with  >500  followers  that  follow  at  least  one  of  the  5  pharma  accounts  listed  above Source:  www.twiJer.com,  Dec  31st  2009;  whdotpharma  analysis 9 Friday, January 29, 2010
  • 11. Boehringer  &  JNJ  :  number  of  followers  with  >  2000  followers   2000-­‐  5000  followers >  5000  followers Source:  www.twiJer.com,  Dec  31st  2009;  whdotpharma  analysis 10 Friday, January 29, 2010
  • 12. Segmented  2,079  unique  pharma  followers  into  6  segments Service  providers:          Consul1ng  services,  agencies,  CROs,  pharma  vendors,  etc. Journalist/bloggers:  Trade,  industry  and  health  publica1ons,            journalists,  financial  analysts,  healthcare  bloggers  etc. Advocacy:                                      Pa1ent  advocacy,  cause/awareness  advocacy  etc. HCP/Stakeholders:        Physicians,  nurses,  regulators,  insurance  etc. Science/academia:        Scien1sts,  scien1fic  publica1ons,  faculty  etc. Other:                                                      Other  pharma  companies,  pharma  employees,            health  websites,  travel  vendors,  real  estate  agents,  other                vendors  individuals,  non-­‐iden1fiable  accounts Source:  www.twiJer.com,  Dec  31st  2009;  whdotpharma  analysis 11 Friday, January 29, 2010
  • 13. Service  providers,  journalists,  bloggers  and   advocates  make  up  57%  of  pharma  following !"#$%&'()'*+,-%&'.//("0*1'23455')(66(+%&17')(66(+,08'*(9'4'9:.&#.'.//("0*1' '304$)5&'6$/078/9$:--./012;$ ,--./012$ !"#$ !%#$ ""#$ "&#$ '#$ (#$ &#$ )&#$ *&#$ %&#$ +&#$ "&&#$ <1=9>$ ?9>@7-9$A>.@7B9>$ C./>0:D721EFD.GG9>2$ ,B@.-:-H$ IJKE?1:L9=.DB9>2$ ?-790M212E,-:B9N7:$ Note:  Analysis  based  on  19%  accounts  with  >500  followers  that  follow  at  least  one  of  the  5  pharma  accounts  listed  above Source:  www.twiJer.com,  Dec  31st  2009;  whdotpharma  analysis 12 Friday, January 29, 2010
  • 14. Service  providers  and  Journalist/bloggers  also  follow  most  of  the  pharma   accounts  with  an  overlap  of  36%  and  41%  respec1vely Service  providers Journalist/bloggers Source:  www.twiJer.com,  Dec  31st  2009;  whdotpharma  analysis 13 Friday, January 29, 2010
  • 15. Boehringer  counts  most  journalists  and  bloggers   amongst  its  followers,  while  JNJ  porholio  is  more  diverse !"#$%&'()'*+,-%&')(..(+%&/'01233')(..(+%&/4'5%&'567&#7'788("9*/'$:'/*7;%6(.<%&'/%=#%9*' Number followers F6G$&H)&($:CC.I3J<K$ (>500) D9/1:4/E$ &'#$ &+#$ ''#$ ')#$ %#$ *#$ Unique 2,079* B.C0/@7.8$ !%#$ &*#$ '&#$ ''#$ *#$ "#$ 506 =>?/1@3/A<$ !%#$ ('#$ '!#$ ,#$ %#$ +#$ 580 6.9:1;<$ !%#$ ()#$ '(#$ %#$ (#$ ,#$ 535 5657.88$ !"#$ (!#$ ''#$ "#$ +#$ (#$ 544 -./01234/1$ !"#$ &(#$ '*#$ ')#$ "#$ +#$ 869 )#$ !)#$ ()#$ +)#$ ")#$ '))#$ Total 3,074 LJ0/1$ M/192C/$N1.92O/1$ 5.I13:P2<JQRP.44/1<$ DO9.C:CS$ T7=QMJ:U/0.PO/1<$ MC2/3;<J<QDC:O/82:$ *  Excluding  overlap  of  32%   Note:  Analysis  based  on  19%  accounts  with  >500  followers  that  follow  at  least  one  of  the  5  pharma  accounts  listed  above Source:  www.twiJer.com,  Dec  31st  2009;  whdotpharma  analysis 14 Friday, January 29, 2010
  • 16. Novar1s  high  overlap  with  others,  Boehringer  followed  by  many   journalists,  bloggers  and  advocates  alone. Advocates Journalist/bloggers Source:  www.twiJer.com,  Dec  31st  2009;  whdotpharma  analysis 15 Friday, January 29, 2010